TY - JOUR

T1 - Transcatheter mitral valve replacement

T2 - Current evidence and concepts

AU - Demir, Ozan M.

AU - Bolland, Mhairi

AU - Curio, Jonathan

AU - Søndergaard, Lars

AU - Rodés-Cabau, Josep

AU - Redwood, Simon

AU - Prendergast, Bernard

AU - Colombo, Antonio

AU - Chau, Mei

AU - Latib, Azeem

N1 - Funding Information: Disclosure: JRC receives institutional research grants from and is a consultant for Edwards Lifesciences, Medtronic and Abbott. AL is a consultant for Edwards Lifesciences, Medtronic and Abbott. All other authors have no conflicts of interest to declare. Received: 21 August 2020 Accepted: 4 January 2021 Citation: Interventional Cardiology Review 2021;16:e07. DOI: https://doi.org/10.15420/icr.2020.25 Correspondence: Azeem Latib, Department of Cardiology, Montefiore Medical Center, 111 East 210th St, Bronx, New York 10467–2401, US. E: alatib@gmail.com Open Access: This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly. Publisher Copyright: © 2021 Radcliffe Group Ltd. All rights reserved.

PY - 2021

Y1 - 2021

N2 - Over the past decade, several transcatheter devices have been developed to address the treatment of severe mitral regurgitation (MR) in patients at high surgical risk, mainly aimed at repairing the native mitral valve (MV). MV repair devices have recently been shown to have high efficacy and safety. However, to replicate promising trial results, specific anatomical and pathophysiological criteria have to be met and operators need a high level of experience. As yet, the longer-term durability of transcatheter MV repair remains unknown. Transcatheter MV replacement (TMVR) might be a treatment option able to target various anatomies, reliably abolish MR, and foster ease of use with a standardised implantation protocol. This review presents upcoming TMVR devices and available data and discusses how TMVR might further advance the field of transcatheter treatment of MR.

AB - Over the past decade, several transcatheter devices have been developed to address the treatment of severe mitral regurgitation (MR) in patients at high surgical risk, mainly aimed at repairing the native mitral valve (MV). MV repair devices have recently been shown to have high efficacy and safety. However, to replicate promising trial results, specific anatomical and pathophysiological criteria have to be met and operators need a high level of experience. As yet, the longer-term durability of transcatheter MV repair remains unknown. Transcatheter MV replacement (TMVR) might be a treatment option able to target various anatomies, reliably abolish MR, and foster ease of use with a standardised implantation protocol. This review presents upcoming TMVR devices and available data and discusses how TMVR might further advance the field of transcatheter treatment of MR.

KW - Heart failure

KW - Mitral regurgitation

KW - Percutaneous mitral valve replacement

KW - Transcatheter mitral valve repair

KW - Transcatheter mitral valve replacement

U2 - 10.15420/ICR.2020.25

DO - 10.15420/ICR.2020.25

M3 - Journal article

AN - SCOPUS:85106931299

VL - 16

JO - Interventional Cardiology: Reviews, Research, Resources

JF - Interventional Cardiology: Reviews, Research, Resources

SN - 1756-1477

M1 - 07

ER -